Avalon GloboCare (Nasdaq:ALBT) - Aandelenkoers, Nieuws & Analyse

ALBT Overzicht aandelen

Avalon GloboCare Corp. bezit en exploiteert samen met haar dochterondernemingen commercieel vastgoed in de Verenigde Staten. Meer informatie

ALBT fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	0/6
Dividenden	0/6

Risicoanalyse

Heeft geen betekenisvolle marktkapitalisatie ( $3M )

Heeft een omzet van minder dan 1 miljoen USD ( $-8M )

Heeft minder dan 1 jaar cash runway

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

+ 1 meer risico

Avalon GloboCare Corp. Concurrenten

Ucommune International

NasdaqCM:UK

US$1.7m

Tuxis

OTCPK:TUXS

US$2.6m

Broad Street Realty

OTCPK:BRST

US$3.7m

New Concept Energy

NYSEAM:GBR

US$6.2m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Avalon GloboCare
Historische aandelenkoersen
Huidige aandelenkoers	US$3.02
52 Week Hoogtepunt	US$21.60
52 Week Laag	US$2.11
Bèta	0.31
11 maand verandering	-7.22%
3 maanden verandering	-39.58%
1 Jaar Verandering	-63.72%
33 jaar verandering	-97.99%
5 jaar verandering	-98.66%
Verandering sinds IPO	-97.12%

Recent nieuws en updates

Recent updates

We Think Some Shareholders May Hesitate To Increase Avalon GloboCare Corp.'s (NASDAQ:ALBT) CEO Compensation

Oct 06

Have Insiders Been Buying Avalon GloboCare Corp. (NASDAQ:AVCO) Shares This Year?

Jan 30

Is Avalon GloboCare (NASDAQ:AVCO) Using Too Much Debt?

Jan 04

What Percentage Of Avalon GloboCare Corp. (NASDAQ:AVCO) Shares Do Insiders Own?

Nov 30

Rendement voor aandeelhouders

	ALBT	US Real Estate	US Markt
7D	-12.2%	-4.6%	-0.5%
1Y	-63.7%	26.6%	32.3%

Rendement versus industrie: ALBT presteerde slechter dan de US Real Estate -sector, die het afgelopen jaar een rendement van 26.6 % opleverde.

Rendement versus markt: ALBT presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 32.3 % opleverde.

Prijsvolatiliteit

Is ALBT's price volatile compared to industry and market?
ALBT volatility
ALBT Average Weekly Movement	27.2%
Real Estate Industry Average Movement	8.1%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.6%
10% least volatile stocks in US Market	3.0%

Stabiele aandelenkoers: De aandelenkoers van ALBT is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van ALBT is het afgelopen jaar gedaald van 50% naar 27%, maar is nog steeds hoger dan 75% van de US -aandelen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2016	5	David Jin	www.avalon-globocare.com

Avalon GloboCare Corp. bezit en exploiteert samen met haar dochterondernemingen commercieel vastgoed in de Verenigde Staten. Het bedrijf richt zich op het ontwikkelen van diagnostiek en klinische laboratoriumdiensten door middel van eigendomsverwerving of licentierechten in precisiediagnostische activa, genetische testen en klinische laboratoriumbedrijven via joint ventures en eigendomsstructuren of distributierechten. Het bedrijf is opgericht in 2016 en heeft zijn hoofdkantoor in Freehold, New Jersey.

Avalon GloboCare Corp. Samenvatting

Hoe verhouden de winst en inkomsten van Avalon GloboCare zich tot de beurswaarde?
ALBT fundamentele statistieken
Marktkapitalisatie	US$3.32m
Inkomsten(TTM)	-US$14.73m
Inkomsten(TTM)	n/a

-0.4x

P/S-verhouding

-0.2x

Koers/Winstverhouding

Is ALBT overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ALBT resultatenrekening (TTM)
Inkomsten	-US$8.32m
Kosten van inkomsten	US$1.03m
Brutowinst	-US$9.35m
Overige uitgaven	US$5.38m
Inkomsten	-US$14.73m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-13.83
Brutomarge	112.38%
Nettowinstmarge	177.07%
Schuld/Eigen Vermogen Verhouding	160.5%

Hoe presteerde ALBT op de lange termijn?

Bekijk historische prestaties en vergelijking

ALBT Overzicht aandelen

Risicoanalyse

Avalon GloboCare Corp. Concurrenten

NasdaqCM:UK

US$1.7m

OTCPK:TUXS

US$2.6m

OTCPK:BRST

US$3.7m

NYSEAM:GBR

US$6.2m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Third quarter 2024 earnings released: US$1.82 loss per share (vs US$2.06 loss in 3Q 2023)

Avalon GloboCare Appoints Dr. Charles Cavo to its Scientific and Clinical Advisory Board

Avalon GloboCare Announces 1-for-15 Reverse Stock Split as Part of Nasdaq Compliance Plan

Avalon GloboCare Corp., Annual General Meeting, Oct 08, 2024

Avalon GloboCare Corp. announced delayed 10-Q filing

Avalon GloboCare Corp. Provides Update on the Launch of the KetoAir Breathalyzer at Hack Your Health by KetoCon 2024 Conference

Recent updates

Third quarter 2024 earnings released: US$1.82 loss per share (vs US$2.06 loss in 3Q 2023)

Avalon GloboCare Appoints Dr. Charles Cavo to its Scientific and Clinical Advisory Board

Avalon GloboCare Announces 1-for-15 Reverse Stock Split as Part of Nasdaq Compliance Plan

Avalon GloboCare Corp., Annual General Meeting, Oct 08, 2024

Avalon GloboCare Corp. announced delayed 10-Q filing

Avalon GloboCare Corp. Provides Update on the Launch of the KetoAir Breathalyzer at Hack Your Health by KetoCon 2024 Conference

Avalon GloboCare Receives Notice from Nasdaq Regarding Delayed Quarterly Report on Form 10-Q for the Fiscal Quarter Ended March 31, 2024

Avalon GloboCare Corp. announced delayed 10-Q filing

The Nasdaq Stock Market, LLC Grants Avalon GloboCare a 180-Day Extension to October 28, 2024 to Regain Compliance with the Minimum Bid Price Requirement

Avalon GloboCare Corp. Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference

Avalon GloboCare Corp. announced delayed annual 10-K filing

Third quarter 2023 earnings released: US$0.14 loss per share (vs US$0.56 loss in 3Q 2022)

Avalon Globocare Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market as Set Forth in Nasdaq Listing Rule 5550(a)(2)

New major risk - Share price stability

We Think Some Shareholders May Hesitate To Increase Avalon GloboCare Corp.'s (NASDAQ:ALBT) CEO Compensation

Avalon GloboCare Corp., Annual General Meeting, Oct 12, 2023

Second quarter 2023 earnings released: US$0.25 loss per share (vs US$0.23 loss in 2Q 2022)

Avalon GloboCare Corp. announced delayed 10-Q filing

Full year 2022 earnings released: US$1.28 loss per share (vs US$1.07 loss in FY 2021)

Avalon GloboCare Corp. announced that it expects to receive $11 million in funding

Avalon GloboCare Regains Compliance with the Minimum Bid Requirement

Avalon Globocare Appoints Lourdes Felix, to Its Board of Directors

Avalon GloboCare Corp., Annual General Meeting, Dec 29, 2022

Third quarter 2022 earnings released: US$0.056 loss per share (vs US$0.024 loss in 3Q 2021)

Insufficient new directors

Avalon GloboCare Corp. (NasdaqCM:AVCO) entered into an agreement to acquire 60% stake in Laboratory Services MSO, LLC for $31 million.

We Think Avalon GloboCare (NASDAQ:AVCO) Has A Fair Chunk Of Debt

Avalon GloboCare Receives Second Letter from the Staff of Nasdaq

Second quarter 2022 earnings released: US$0.023 loss per share (vs US$0.028 loss in 2Q 2021)

Avalon GloboCare Corp. Announces New Study Featuring AI-Enhanced Protein Design Technology Targeting Glucose Transporter Against Cancer

Avalon GloboCare Corp. announced that it has received $3.718943 million in funding

Insufficient new directors

Would Avalon GloboCare (NASDAQ:AVCO) Be Better Off With Less Debt?

Avalon GloboCare Corp. Appoints Hongxing Liu to Scientific and Clinical Advisory Board

First quarter 2022 earnings released: US$0.023 loss per share (vs US$0.028 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings released: US$0.11 loss per share (vs US$0.16 loss in FY 2020)

Does Avalon GloboCare (NASDAQ:AVCO) Have A Healthy Balance Sheet?

Avalon GloboCare Expands its Cellular Immuno-Oncology Platform with the Addition of Novel Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapies

Third quarter 2021 earnings released: US$0.024 loss per share (vs US$0.04 loss in 3Q 2020)

Here's Why Avalon GloboCare (NASDAQ:AVCO) Can Afford Some Debt

Director William Stilley has joined 3rd company board

Second quarter 2021 earnings released: US$0.028 loss per share (vs US$0.039 loss in 2Q 2020)

Avalon GloboCare Corp.(NasdaqCM:AVCO) dropped from Russell Microcap Value Index

Avalon GloboCare Corp. (NasdaqCM:AVCO) entered into a definitive agreement to acquire Hebei Senlang Biotechnology Inc., Ltd. for approximately CNY 640 million.

Avalon Globocare to acquire SenlangBio in all-stock deal

First quarter 2021 earnings released: US$0.028 loss per share (vs US$0.043 loss in 1Q 2020)

Is Avalon GloboCare (NASDAQ:AVCO) A Risky Investment?

Full year 2020 earnings released: US$0.16 loss per share (vs US$0.24 loss in FY 2019)

A Look At Avalon GloboCare's (NASDAQ:AVCO) Share Price Returns

New 90-day high: US$1.59

Have Insiders Been Buying Avalon GloboCare Corp. (NASDAQ:AVCO) Shares This Year?

New 90-day high: US$1.33

Is Avalon GloboCare (NASDAQ:AVCO) Using Too Much Debt?

What Percentage Of Avalon GloboCare Corp. (NASDAQ:AVCO) Shares Do Insiders Own?

Third quarter 2020 earnings released: US$0.04 loss per share

New 90-day low: US$1.12

Avalon GloboCare Provides Clinical Updates on its CAR-T Immuno-Oncology and Allogeneic Mesenchymal Stromal Cell (MSC) Therapy Programs Following Successful Completion of Phase I AVA-001 Clinical Trial

New 90-day low: US$1.15

New 90-day low - US$1.54